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Purpose: The prostate-specific antigen (PSA) level decreases after transurethral re-
section of the prostate (TURP). However, changes in the PSA level after potassium-ti-
tanyl-phosphate (KTP) laser vaporization of the prostate are not well known. The aim 
of this study was to investigate the effect of KTP laser vaporization of the prostate on 
PSA levels in patients with benign prostatic hyperplasia (BPH).
Materials and Methods: Serum PSA levels were checked before and 1, 3, 6, and 12 
months after the procedure in patients who underwent KTP laser vaporization between 
October 2004 and August 2008. Patients with prostate cancer, a history of urinary re-
tention, or prostatitis during the follow-up period were excluded. The results for 278 
patients were studied.
Results: The mean age of the patients was 69.0±6.7 years (range, 50-91 years) and the 
mean preoperative PSA level was 2.72±2.93 ng/ml. The PSA level tended to be increased 
at 1 month after the operation (3.18±3.23 ng/ml, p=0.032) but decreased within 3 
months and became stabilized after 6 months at 1.79±1.82 ng/ml (p＜0.001).
Conclusions: PSA levels may increase after KTP laser vaporization for a certain period 
of time, but eventually decrease and become stabilized after 6 months. Therefore, it 
may be appropriate to wait up to 3 months if the PSA level rises after the procedure, 
and further investigation should be considered if the PSA level still remains high after 
6 months.
Key Words: Prostate-specific antigen; Potassium titanyl-phosphate; Prostatic hyper-
plasia
Article History:
received 27 November, 2009
accepted 4 January, 2010
Corresponding Author:
Tai Young Ahn
Department of Urology, Asan Medical 
Center, University of Ulsan College of 
Medicine, 388-1, Pungnap-dong, 
Songpa-gu, Seoul 138-736, Korea
TEL: +82-2-3010-3736
FAX: +82-2-477-8928
E-mail: tyahn@amc.seoul.kr
INTRODUCTION
Since prostate-specific antigen (PSA) was demonstrated in 
prostatic tissue in 1970, measurement of the serum PSA 
level has become widely used for the early diagnosis and 
management of prostate cancer [1]. However, it is well 
known that an increased serum PSA level does not always 
indicate the existence of prostate cancer [2,3]. The serum 
PSA level can also be increased in patients with benign pro-
static hyperplasia (BPH), in patients with prostatitis, and 
after interventions such as prostate biopsy and transure-
thral resection of the prostate (TURP) [2,3]. Especially in 
patients with mildly increased serum PSA (4-10 ng/ml), the 
single most common cause of serum PSA elevation is 
known to be BPH, rather than prostate cancer. Other be-
nign prostatic diseases that can cause elevation of the se-
rum PSA level include acute urinary retention, acute pros-
tatitis, and prostatic ischemia [4]. Moreover, it has been re-
ported that the serum PSA level has a tendency to increase 
temporarily for 20 days after TURP and will decrease after-
wards [2]. Therefore, it is difficult to distinguish prostate 
cancer from benign prostatic conditions in patients who 
have undergone interventions on the prostate. One report 
on this issue suggested that 3% of patients who have under-
gone surgeries for BPH will actually develop prostate can-
cer during the follow-up period [5]; thus, establishment of 
clinical guidelines for follow-up strategies for such patients 
is necessary.
　It is now well understood from several reports on changes 
in the serum PSA level after TURP that the serum PSA lev-
el decreases after TURP [2,6]. By contrast, reports on 
changes in the serum PSA level after potassium-titanyl- Korean J Urol 2010;51:111-114
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TABLE 1. Baseline variables
Variables Mean±SD Range
Age (years)
Preoperative PSA (ng/ml)
Prostate volume (cc)
Energy applied (kJ)
Operation time (min)
69.0±6.7
2.72±2.93
35.7±15.5
161.9±112.0
46.5±13.9
50-91
0.1-19.4
12-102
11.7-486.6
25-97
PSA: prostate-specific antigen, SD: standard deviation
TABLE 2. Changes in postoperative follow-up PSA
Time Mean PSA (ng/ml) PSA changed (ng/ml) 95% CI p-value
a
Preoperative
1 month after
3 months after
6 months after
12 months after
24 months after
b
2.72
3.18
1.92
1.79
1.70
1.71
＋0.46
−0.80
−0.93
−1.02
−1.01
1.29-1.50
2.08-2.95
0.95-1.23
0.89-1.17
0.76-1.01
0.64-1.32
　0.032
＜0.001
＜0.001
＜0.001
　0.041
PSA: prostate-specific antigen, CI: confidence interval, 
a: p-value of changes compare to preoperative PSA, 
b: measured in only 183 pa-
tients among the enrolled patients
phosphate (KTP) laser vaporization of the prostate based 
on the analysis of large populations are rare.
　Treatment of patients with BPH by 80 W high-power 
KTP laser vaporization was first introduced in clinical 
practice in 2000 and is now accepted as an effective mini-
mally invasive treatment modality. This method elimi-
nates prostatic tissues that cause obstruction through va-
porization, which occurs when hemoglobin selectively ab-
sorbs the KTP laser that generates heat energy [7].
　KTP laser vaporization has gained considerable atten-
tion among many urologists recently because this treat-
ment modality is less invasive while offering treatment re-
sults similar to those of conventional TURP [8,9]. Hwang 
et al reported that patients who underwent KTP laser va-
porization demonstrated significant improvements in 
International Prostate Symptom Score (IPSS), maximal 
flow rate (Qmax), quality of life (QoL), and residual urine 
3 months after the operation [9].
　Because the use of KTP laser vaporization is expected to 
increase, a need exists for establishing patterns in changes 
in the serum PSA level after the operation. The elucidation 
of such patterns might offer useful clinical information on 
appropriate management and follow-up strategies.
MATERIALS AND METHODS
A total of 662 patients underwent KTP laser vaporization 
of the prostate for BPH between October 2004 and August 
2008. Among these patients, those with prostate cancer, 
prostatitis, a history of urinary retention, or use of anti-
androgen medication, all of which can influence serum PSA 
levels, were excluded. Also excluded were patients for 
whom insufficient data were available or who were lost to 
follow-up. Therefore, 278 patients were included in the pro-
spective analysis of serial serum PSA levels.
　Careful history taking, digital rectal examination 
(DRE), IPSS, urinalysis/urine culture, transrectal ultra-
sound (TRUS), Qmax, postvoiding residual urine (PVR), 
and serum PSA levels were checked in every enrolled pa-
tient and evaluated to determine whether to perform KTP 
laser vaporization. Patients with abnormal DRE findings 
or a serum PSA value of 4.0 ng/ml or higher underwent 
TRUS-guided 12-core prostate biopsy to detect and exclude 
prostate cancer. Prostate volume was estimated by TRUS, 
first by measuring length (L), width (W), and height (H) and 
then by calculating volume by use of a prolate ellipsoid for-
mula (LxWxHxπ/6).
　Either epidural or subarachnoid anesthesia was used for 
the operations, and the vaporization was carried out by use 
of an 80 W KTP laser system (GreenLight
Ⓡ PVTM; Laser-
scope, San Jose, CA) that uses a 6 Fr side-deflecting optical 
fiber emitting laser at a wavelength of 532 nm, which is de-
livered through a 23 Fr, 30
o continuous flow cystoscope con-
nected to videoendoscopy. The distance from the probe to 
the prostatic tissue was kept closer than 2 mm, and normal 
saline was used as the irrigation fluid. The vaporization 
was performed until the tissues that caused the ob-
struction were completely removed, resulting in the for-
mation of an appropriately sized cavity. A Foley catheter 
(16 or 18 Fr) was inserted right after the procedure and was 
removed one day later.
　Serum PSA levels were measured in every patient before 
the operation and 1, 3, 6, and 12 months after the operation 
to analyze patterns of change. In addition, serum PSA lev-
els at 24 months after the operation were also checked in 
183 patients. The mixed linear model in SPSS (version 
12.0, SPSS Inc) was used for statistical analysis of the 
changes in the serum PSA level, and statistical significance 
was defined as a p-value of less than 0.05.
RESULTS
The mean age of the patients was 69.0 years (range, 50-91 
years). The mean serum PSA value was 2.72±2.93 ng/ml, 
and mean prostate volume estimated by TRUS was 
35.7±15.5 cc (Table 1).
　The serum PSA level temporarily increased and reached Korean J Urol 2010;51:111-114
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FIG. 1. Patterns of change in the PSA level before and after KTP
laser vaporization of the prostate. PSA: prostate-specific anti-
gen, KTP: potassium-titanyl-phosphate.
3.18±3.23 ng/ml at 1 month after the operation (p=0.032). 
However, levels began to decrease continuously afterward 
and decreased to 1.92±2.26 ng/ml in 3 months (p＜0.001) 
and 1.79±1.82 ng/ml in 6 months (p＜0.001). Within 12 
months, the serum PSA level was 1.70±2.25 ng/ml (p＜ 
0.001), thus demonstrating a decreasing pattern of stabili-
zation (Table 2, Fig. 1). The decreasing pattern showed its 
greatest value between 1 month and 6 months (Fig. 1). The 
serum PSA level at 24 months after the operation was not 
checked in all patients, but it also was shown to decrease 
and stabilize (Table 2). As a result, the serum PSA level had 
decreased by 37.5% by 12 months after the operation com-
pared with the preoperative level.
DISCUSSION
BPH is a common disease in older men; 40% to 70% of men 
over the age of 60 years are suspected of having BPH, and 
it is still on the rise along with increasing life expectancy 
and westernized diets [10,11]. TURP is accepted as the 
standard surgical method for treating the lower urinary 
tract symptoms of BPH, although several other treatment 
options have been developed to date. However, complica-
tions of TURP such as bleeding, TUR syndrome, urethral 
stricture, retrograde ejaculation, and urinary incon-
tinence are still among the side effects of this procedure and 
have not decreased significantly despite developments in 
techniques and instruments. Accordingly, less invasive 
surgical options have been investigated [8].
　KTP laser vaporization of the prostate was introduced 
in the 1990s but was not widely accepted as an effective 
treatment option because it was performed with a low-pow-
er (20 W, 34 W) KTP laser in the early years and required 
a relatively longer surgical time than conventional TURP. 
More recently, however, the 80 W high-power KTP laser 
was developed to improve vaporization speed, and as a re-
sult, KTP laser vaporization has become an effective treat-
ment modality. Malek et al proved its efficacy by reporting 
that patients with prostates over 45 cc who underwent 80 
W KTP laser vaporization showed significant improve-
ments in IPSS, QoL, Qmax, and PVR within 5 years of fol-
low-up [12]. Therefore, KTP vaporization is now widely 
practiced in many institutes because of its efficacy and re-
duced invasiveness, even though some controversy re-
mains concerning its complication rates compared with 
conventional TURP [13-15].
　KTP laser vaporization cannot eradicate prostate cancer 
that originates in the peripheral zone, however, because it 
only eliminates tissues at the transitional zone of the pros-
tate [6,16]. Marks et al reported that among 82 patients 
who underwent TURP to treat lower urinary tract symp-
toms, prostate cancer had developed in 6 patients within 
5 years of follow-up [6]. With KTP laser vaporization in par-
ticular, possible pathologic diagnosis of prostate cancer 
could be missed because it is impossible to obtain a prostate 
specimen from the operation, which is possible in conven-
tional TURP. Therefore, it would be useful to establish clin-
ical guidelines by serum PSA follow-up after the operation 
to detect coexisting prostate malignancy with BPH. To 
date, however, only limited reports on serum PSA changes 
after KTP laser vaporization of the prostate were available.
　It is widely known that serum PSA levels generally in-
crease after interventions on the prostate for a certain peri-
od of time and decrease afterward [2,17]. Temporary ele-
vation of the serum PSA level occurs as a result of PSA leak-
age to the systemic circulation due to damage to the 
blood-prostate barrier during manipulations [18]. In addi-
tion, prostatic inflammation after the manipulation can al-
so facilitate increases in the serum PSA level [2]. There are 
several different reports on the length of time it takes for 
the serum PSA level to decrease after a procedure. Volkan 
et al reported that the serum PSA level increased immedi-
ately after KTP laser vaporization, but eventually de-
creased and returned to its preoperative level within 15 
days after the operation [19]. In our series, the serum PSA 
level increased for up to 1 month and then decreased sig-
nificantly over the next 3 months. It is not possible to clearly 
explain this variability in the length of time for which the 
serum PSA level is increased. Further investigation of the 
probable responsible factors, such as differences in pros-
tate volume, the preoperative serum PSA level, operating 
time, and devices, are necessary to clarify this matter.
　Aus et al analyzed the serum PSA level of 190 patients 
who underwent TURP and reported that the serum PSA 
level was reduced by 70% compared with its preoperative 
level [20]. They also reported that the serum PSA level be-
came lower than 4 ng/ml in 90% of those patients. Wolff et 
al also reported that the serum PSA level became stabilized 
at 2 ng/ml or higher in patients who were diagnosed with 
prostate cancer after TURP [21]. Therefore, similar to pa-
tients who undergo TURP, the possible existence of pros-
tate cancer should also be considered in patients who dem-
onstrate a serum PSA level that remains high or increases 
constantly after KTP laser vaporization. In our study, the Korean J Urol 2010;51:111-114
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serum PSA level decreased significantly within 3 months 
after the operation and showed only a slight decrease from 
6 to 12 months, which might mean that the levels stabilize 
after 6 months.
　In the present study, we were able to accurately analyze 
the changes in the serum PSA level after KTP laser vapor-
ization by frequently checking the postoperative serum 
PSA level in a relatively large population for more than 1 
year. Our results might provide valuable guidelines for 
clinical practice.
CONCLUSIONS
The serum PSA level may be temporarily increased after 
KTP laser vaporization for a certain period of time, but val-
ues will show a decreasing pattern within 3 months and will 
eventually become stabilized between 6 and 12 months. 
Therefore, it may be appropriate to wait for 3 months if the 
serum PSA level rises after the procedure. However, if the 
serum PSA level remains high even after 6 months, close 
follow-up or further investigation should be considered.
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